KRRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Korro Bio Inc (KRRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong positive sentiment from analysts, hedge fund buying, and a promising pipeline in addressing unmet medical needs. Despite weak technical indicators and recent financial challenges, the long-term growth potential and analyst upgrades make this a favorable investment opportunity.
The technical indicators are currently bearish. The MACD histogram is negative (-0.136) but contracting, RSI is neutral at 42.293, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near a key support level (S1: 10.597), with resistance levels at R1: 13.89 and R2: 14.907.
Strong analyst upgrades with price targets ranging from $15 to $30, citing promising preclinical data and a pivot into high unmet need areas like hyperammonemia.
Hedge funds are significantly increasing their positions, with a 1445.31% increase in buying over the last quarter.
KRRO-121's potential to address unmet medical needs with strong scientific rationale and regulatory path ahead.
Weak technical indicators with bearish moving averages and neutral RSI.
Recent financial performance shows a revenue drop of -43.11% YoY, though net income and EPS have improved.
Lack of recent news and no congress trading data to provide additional sentiment insights.
In Q4 2025, revenue dropped by -43.11% YoY to $1,292,000. However, net income improved significantly to -$50,042,000 (up 136.06% YoY), and EPS increased to -5.32 (up 135.40% YoY). Gross margin remains strong at 100%.
Analysts are overwhelmingly bullish on KRRO, with multiple upgrades to Buy or Outperform and price targets ranging from $15 to $30. Analysts highlight the potential of KRRO-121 to address unmet medical needs and the company's pivot into high-value therapeutic areas.
